Apellis Pharmaceuticals, Inc. (BIT:1APLS)
19.01
0.00 (0.00%)
At close: Oct 10, 2025
Apellis Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Cash & Equivalents | 370.04 | 411.29 | 351.19 | 551.8 | 640.19 | 565.78 | Upgrade |
Short-Term Investments | - | - | - | - | 60.36 | 311.87 | Upgrade |
Cash & Short-Term Investments | 370.04 | 411.29 | 351.19 | 551.8 | 700.55 | 877.65 | Upgrade |
Cash Growth | 2.76% | 17.11% | -36.36% | -21.23% | -20.18% | 149.34% | Upgrade |
Accounts Receivable | 214.13 | 264.93 | 206.44 | 7.73 | 10.1 | - | Upgrade |
Inventory | 121 | 81.4 | 146.36 | 85.71 | 16.29 | - | Upgrade |
Other Current Assets | 50.44 | 31.33 | 62.34 | 74.28 | 97.11 | 39.54 | Upgrade |
Total Current Assets | 755.61 | 788.95 | 766.33 | 719.52 | 824.05 | 917.19 | Upgrade |
Net Property, Plant & Equipment | 16.75 | 19.04 | 21.09 | 24.9 | 26.08 | 24.52 | Upgrade |
Other Long-Term Assets | 49.03 | 77.06 | 1.31 | 15.8 | 31.64 | 18.86 | Upgrade |
Total Assets | 821.39 | 885.05 | 788.73 | 760.22 | 881.77 | 960.57 | Upgrade |
Accounts Payable | 54.24 | 38.57 | 37.52 | 37.34 | 16.91 | 8.48 | Upgrade |
Accrued Expenses | 139 | 140.18 | 127.81 | 95.14 | 103.24 | 111.94 | Upgrade |
Current Portion of Leases | 7.42 | 6.75 | 6.44 | 5.63 | 4.12 | 3.69 | Upgrade |
Other Current Liabilities | - | - | 75.83 | 29.5 | 7.58 | 4.23 | Upgrade |
Total Current Liabilities | 200.66 | 185.51 | 247.59 | 167.61 | 131.85 | 128.33 | Upgrade |
Long-Term Debt | 454.04 | 452.83 | 93.03 | 92.74 | 189.02 | 358.83 | Upgrade |
Long-Term Leases | 8.31 | 10.2 | 11.45 | 14.35 | 17.08 | 15.22 | Upgrade |
Other Long-Term Liabilities | 2.08 | 7.97 | 242.13 | 315.65 | 345.15 | 253.64 | Upgrade |
Total Long-Term Liabilities | 464.43 | 471 | 346.62 | 422.74 | 551.26 | 627.69 | Upgrade |
Total Liabilities | 665.09 | 656.51 | 594.21 | 590.35 | 683.1 | 756.01 | Upgrade |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade |
Additional Paid-in Capital | 3,329 | 3,267 | 3,036 | 2,480 | 1,857 | 1,131 | Upgrade |
Accumulated Other Comprehensive Income | -2.57 | -3.31 | -3.54 | -0.88 | -2.09 | -0.12 | Upgrade |
Retained Earnings | -3,170 | -3,035 | -2,837 | -2,309 | -1,657 | -926.35 | Upgrade |
Shareholders' Equity | 156.31 | 228.54 | 194.52 | 169.87 | 198.66 | 204.56 | Upgrade |
Total Liabilities & Equity | 821.39 | 885.05 | 788.73 | 760.22 | 881.77 | 960.57 | Upgrade |
Total Debt | 469.77 | 469.78 | 110.93 | 112.71 | 210.22 | 377.73 | Upgrade |
Net Cash (Debt) | -99.73 | -58.49 | 240.26 | 439.09 | 490.33 | 499.92 | Upgrade |
Net Cash Growth | - | - | -45.28% | -10.45% | -1.92% | 156.43% | Upgrade |
Net Cash Per Share | -0.80 | -0.47 | 2.02 | 4.14 | 5.81 | 6.65 | Upgrade |
Book Value | 156.31 | 228.54 | 194.52 | 169.87 | 198.66 | 204.56 | Upgrade |
Book Value Per Share | 1.25 | 1.84 | 1.64 | 1.60 | 2.35 | 2.72 | Upgrade |
Tangible Book Value | 156.31 | 228.54 | 194.52 | 169.87 | 198.66 | 204.56 | Upgrade |
Tangible Book Value Per Share | 1.25 | 1.84 | 1.64 | 1.60 | 2.35 | 2.72 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.